论文部分内容阅读
Objective: The aim of this study was to compare the efficacies and safeties of the combination of docetaxel-carboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian,primary peritoneal or fallopian tube cancers.Methods: Relevant articles were identified from MEDLINE(1993-2010),EMBASE(1980-2010),MEDION,the Cochrane library,Science Citation Index Expanded databases,hand searching of reference lists from primary articles and reviews,conference abstracts and contact with experts in the field.The review included 5 relevant primary studies(1430 women).Data was extracted for study characteristics and quality.Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests.A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.Results: The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxel-carboplatin group(OR=1.33,95% CI=1.13-1.56,P=0.0005),whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin(OR=1.0,95%CI=0.87-1.16,P=0.95).There were heterogeneity(χ2=79.36,P